Verastem, Inc. (NASDAQ:VSTM) Gains Momentum Among Investors

• RBC Capital sets a price target of $13 for Verastem, indicating a potential increase of 62.3%.

• Zacks Investment Research assigns Verastem a Momentum Style Score of A, highlighting its potential for continued positive performance.

• Wall Street analysts project price targets ranging from $13 to $20, suggesting potential increases of 41% to 116.9%.

Verastem, Inc. (NASDAQ:VSTM) is a biopharmaceutical company focused on developing and commercializing medicines to improve the lives of cancer patients. The company is gaining attention in the investment community, particularly among momentum investors. Momentum investing involves buying stocks that have shown an upward trend, with the expectation that the trend will continue. Verastem's recent performance and analyst projections make it a compelling choice for such investors.

On October 20, 2025, RBC Capital set a price target of $13 for Verastem, as reported by TheFly. At that time, the stock was priced at $8.01, suggesting a potential increase of 62.3% to reach the target. Despite a slight decline in the stock, RBC Capital considers Verastem's data to be 'best-in-class', which could drive future growth.

Zacks Investment Research highlights Verastem as a top pick for momentum investors, assigning it a Momentum Style Score of A. This score indicates strong potential for continued positive performance. The stock is currently trading at $9.22, having gained 1.9% over the past four weeks. Analysts have set a mean price target of $15.5, suggesting a potential 68.1% increase in value.

The stock's price has fluctuated, with a recent decrease of 7.97% to $8.49. It has traded between $6.98 and $9.02 today, and over the past year, it has ranged from a low of $2.95 to a high of $11.25. Verastem's market capitalization is approximately $522.2 million, with a trading volume of 4,762,954 shares on the NASDAQ exchange.

Wall Street analysts are optimistic about Verastem's future, with price targets ranging from $13 to $20. This range suggests potential increases of 41% to 116.9%. The standard deviation of $2.62 among these estimates indicates moderate agreement among analysts. While the consensus price target is a useful metric, investors should consider other factors before making decisions.